The Lancet Oncology: Targeted treatments for pancreatic cancer may help eligible patients live an extra year

Patients with molecular changes in their tumors who received a targeted therapy alongside other treatment survived for an average of one year longer after being diagnosed with advanced disease compared with patients who received standard chemotherapy (survival of 31 vs. 18 months), according to an observational study published in The Lancet Oncology journal.